COMMUNIQUÉS West-GlobeNewswire

Intellia Therapeutics to Hold Conference Call to Discuss Third Quarter 2018 Earnings and Corporate Developments
30/10/2018
CAMBRIDGE, Mass., Oct. 30, 2018 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and [...]
Osiris Therapeutics, Inc. to Present Advanced Clinical and Scientific Abstracts at Symposium on Advanced Wound Care (SAWC) Fall Meeting, November 2-4, 2018, in Las Vegas, Nevada
30/10/2018
COLUMBIA, Md., Oct. 30, 2018 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (NASDAQ: OSIR), a regenerative medicine company focused on developing and marketing products for wound care, orthopedics, and sports medicine, [...]
Profound Medical to Release Third Quarter 2018 Financial Results on November 8 – Conference Call to Follow
30/10/2018
TORONTO, Oct. 30, 2018 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX:PRN; OTCQX:PRFMF) (“Profound” or the “Company”), the only company to provide a therapeutics platform that provides the precision of real-time [...]
CooperSurgical, Inc. Launches PGTai Technology Platform and ERPeak Endometrial Receptivity Test
30/10/2018
TRUMBULL, Conn., Oct. 30, 2018 (GLOBE NEWSWIRE) -- CooperSurgical, Inc. announced the launch of the CooperGenomics SM PGTai SM technology platform and ERPeak SM endometrial receptivity test at ASRM 2018. The PGTai SM [...]
CymaBay to Report Third Quarter 2018 Financial Results on Tuesday, November 6
30/10/2018
NEWARK, Calif., Oct. 30, 2018 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (Nasdaq: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high [...]
Prothena to Report Third Quarter 2018 Financial Results on November 6
30/10/2018
DUBLIN, Ireland, Oct. 30, 2018 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a clinical-stage neuroscience company, will announce financial results for the third quarter and first nine months of 2018 on [...]
Cutera to Present at Three Upcoming Healthcare Conferences
30/10/2018
BRISBANE, Calif., Oct. 30, 2018 (GLOBE NEWSWIRE) -- CUTERA, INC., (Nasdaq: CUTR ) (“Cutera” or the “Company”) a leading provider of laser, light and other energy-based aesthetic systems for practitioners worldwide, [...]
BioTelemetry, Inc. Reports Third Quarter 2018 Financial Results
30/10/2018
Company’s Results Exceed Expectations Company Raises Full-Year Guidance MALVERN, Pa., Oct. 30, 2018 (GLOBE NEWSWIRE) -- BioTelemetry, Inc. (NASDAQ:BEAT), the leading remote and wireless medical technology company [...]
KemPharm Enters Into License Agreement with KVK Tech for the Commercialization of APADAZ®
30/10/2018
Partnership with KVK, One of the Largest Manufacturers of Controlled Substances in the U.S., Opens the Door for Commercial Launch of APADAZ with PBMs and MCOs KemPharm to Host a Conference Call Today, Tuesday, October [...]
electroCore, Inc. to Report Third Quarter Financial Results on November 13, 2018
30/10/2018
BASKING RIDGE, N.J., Oct. 30, 2018 (GLOBE NEWSWIRE) -- electroCore, Inc. (“electroCore”) (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that it will release financial results for the [...]
Myriad Genetics to Present at the Stephens New York Investment Conference
30/10/2018
SALT LAKE CITY, Oct. 30, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and personalized medicine, announced today that R. Bryan Riggsbee, CFO, is scheduled to present [...]
CytomX Therapeutics to Announce Third Quarter 2018 Financial Results
30/10/2018
SOUTH SAN FRANCISCO, Calif., Oct. 30, 2018 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody [...]
Cara Therapeutics to Announce Third Quarter 2018 Financial Results on November 6, 2018
30/10/2018
STAMFORD, Conn., Oct. 30, 2018 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus and [...]
Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2018 Financial Results and Provide Corporate Update
30/10/2018
BURNABY, British Columbia, Oct. 30, 2018 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that it will report its third quarter 2018 financial and [...]
Aduro Biotech Reports Third Quarter 2018 Financial Results
30/10/2018
BERKELEY, Calif., Oct. 30, 2018 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO) today reported financial results for the third quarter ended September 30, 2018. Net loss for the third quarter of 2018 was $23.1 [...]
Cerecor Receives Rare Pediatric Disease Designation for CERC-801 for Patients with Inborn Error of Metabolism
30/10/2018
BALTIMORE, Oct. 30, 2018 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases in [...]
Changes in Clocks and Amount of Light Affect Sleep and Health - Tips from a Sleep Physician to Successfully Deal with Fall’s Time Change and Reduced Daylight Hours
30/10/2018
CALGARY, Alberta, Oct. 30, 2018 (GLOBE NEWSWIRE) -- The clocks go back an hour at 02:00 AM Sunday morning, providing an extra hour of much needed sleep. “As many as 30 per cent of people in society are chronically sleep [...]
OSE Immunotherapeutics Presents Selective SIRP-alpha antibodies: OSE-172, a next-generation myeloid checkpoint inhibitor at the World Immunotherapy Congress
30/10/2018
Basel, Oct. 29-31, 2018 NANTES, France, Oct. 30, 2018 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnémo: OSE) presented at the World Immunotherapy Congress held on Oct. 29-31, 2018 in Basel, [...]
NEOVACS : HALF-YEAR 2018 FINANCIAL RESULTS
30/10/2018
PRESS RELEASE · PRESS RELEASE · PRESS RELEASE HALF-YEAR 2018 FINANCIAL RESULTS STRENGTHENED CASH POSITION: € 4.7 M AT JUNE 30 2018 VS € 1.7 M AT JUNE 30 2017 LOWER OPERATING COSTS, CONSISTENT WITH THE END OF THE [...]

Pages